Marietta Wealth Management LLC Has $6.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Marietta Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 6.2% in the 2nd quarter, bringing its holdings to approximately $6.01 million consisting of 11,451 shares.
• Regeneron Pharmaceuticals reported $12.89 earnings per share for its last quarter, significantly exceeding analysts' expectations of $8.43, with a revenue of $3.68 billion.
• The company announced a quarterly dividend of $0.88 per share, equating to an annualized yield of 0.6%, highlighting strong financial performance amidst favorable market perceptions.

Marietta Wealth Management LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 6.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,451 shares of the biopharmaceutical company's stock after buying an additional 673 shares during the quarter. Marietta Wealth Management LLC's holdings in Regeneron Pharmaceuticals were worth $6,012,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Checchi Capital Advisers LLC grew its holdings in Regeneron Pharmaceuticals by 7.3% during the second quarter. Checchi Capital Advisers LLC now owns 732 shares of the biopharmaceutical company's stock worth $384,000 after buying an additional 50 shares in the last quarter. Willner & Heller LLC grew its holdings in Regeneron Pharmaceuticals by 18.7% during the second quarter. Willner & Heller LLC now owns 469 shares of the biopharmaceutical company's stock worth $246,000 after buying an additional 74 shares in the last quarter. Quent Capital LLC grew its holdings in Regeneron Pharmaceuticals by 9.8% during the second quarter. Quent Capital LLC now owns 438 shares of the biopharmaceutical company's stock worth $230,000 after buying an additional 39 shares in the last quarter. 111 Capital bought a new stake in Regeneron Pharmaceuticals during the second quarter worth $517,000. Finally, Ameritas Advisory Services LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter worth $45,000. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on REGN. Jefferies Financial Group upped their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a report on Wednesday, August 27th. Royal Bank Of Canada upped their price objective on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Guggenheim upped their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research note on Friday, August 1st. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research note on Monday, August 4th. Finally, Sanford C. Bernstein upped their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research note on Wednesday, August 27th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $817.67.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $600.00 on Friday. The firm has a market cap of $63.59 billion, a P/E ratio of 15.12, a P/E/G ratio of 1.92 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,024.36. The business's 50 day moving average price is $572.12 and its 200-day moving average price is $567.22. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the company earned $11.56 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.